Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes.
Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, Pagliuca A, Cornelissen JJ, Schouten HC, Carreras E, Finke J, van Biezen A, Brand R, Niederwieser D, Gluckman E, de Witte TM; Subcommittee for Myelodysplastic Syndromes of the Chronic Leukaemia Working Group of the European Blood and Marrow Transplantation Group. Guardiola P, et al. Among authors: pagliuca a. Blood. 2002 Jun 15;99(12):4370-8. doi: 10.1182/blood.v99.12.4370. Blood. 2002. PMID: 12036864 Free article.
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.
Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG, Potter M, Pagliuca A, Ho A, Devereux S, McQuaker G, Mufti G, Yin JL, Russell NH. Faulkner RD, et al. Among authors: pagliuca a. Blood. 2004 Jan 15;103(2):428-34. doi: 10.1182/blood-2003-05-1406. Epub 2003 Sep 11. Blood. 2004. PMID: 12969983 Free article.
Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002.
Gennery AR, Khawaja K, Veys P, Bredius RG, Notarangelo LD, Mazzolari E, Fischer A, Landais P, Cavazzana-Calvo M, Friedrich W, Fasth A, Wulffraat NM, Matthes-Martin S, Bensoussan D, Bordigoni P, Lange A, Pagliuca A, Andolina M, Cant AJ, Davies EG. Gennery AR, et al. Among authors: pagliuca a. Blood. 2004 Feb 1;103(3):1152-7. doi: 10.1182/blood-2003-06-2014. Epub 2003 Oct 2. Blood. 2004. PMID: 14525761 Free article.
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.
Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, Mufti GJ. Ho AY, et al. Among authors: pagliuca a. Blood. 2004 Sep 15;104(6):1616-23. doi: 10.1182/blood-2003-12-4207. Epub 2004 Apr 1. Blood. 2004. PMID: 15059843 Free article. Clinical Trial.
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J, Potter V, Koh MB, Islam MS, Russell N, Marks DI, Mufti GJ, Pagliuca A. Marsh JC, et al. Among authors: pagliuca a. Blood. 2011 Aug 25;118(8):2351-7. doi: 10.1182/blood-2010-12-327536. Epub 2011 Apr 25. Blood. 2011. PMID: 21518925 Free article. Clinical Trial.
Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC, Devereux S, Pagliuca A, Mufti GJ. Krishnamurthy P, et al. Among authors: pagliuca a. Biol Blood Marrow Transplant. 2013 Apr;19(4):562-8. doi: 10.1016/j.bbmt.2012.12.013. Epub 2012 Dec 21. Biol Blood Marrow Transplant. 2013. PMID: 23266740 Free article.
Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.
Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, McLornan D, Kazmi M, Marsh J, Kwan J, Huang G, Getzendaner L, Lee S, Guthrie KA, Mufti GJ, O'Donnell P. Raj K, et al. Among authors: pagliuca a. Biol Blood Marrow Transplant. 2014 Jun;20(6):890-5. doi: 10.1016/j.bbmt.2014.03.003. Epub 2014 Mar 18. Biol Blood Marrow Transplant. 2014. PMID: 24650678 Free PMC article.
Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation.
Pascal L, Tucunduva L, Ruggeri A, Blaise D, Ceballos P, Chevallier P, Cornelissen J, Maillard N, Tabrizi R, Petersen E, Linkesch W, Sengeloev H, Kenzey C, Pagliuca A, Holler E, Einsele H, Gluckman E, Rocha V, Yakoub-Agha I; Eurocord and the European Society for Blood and Marrow Transplantation. Pascal L, et al. Among authors: pagliuca a. Blood. 2015 Aug 20;126(8):1027-32. doi: 10.1182/blood-2014-09-599241. Epub 2015 Jul 9. Blood. 2015. PMID: 26160301 Free article.
253 results